CoChat

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.Methods This retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy. Patients were classified according to BMI, following the WHO definitions, as underweight, normal, overweight, or obese. Patients without BMI and underweight patients were excluded. The primary outcomes were the associations between BMI and progression-free survival or overall survival, stratified by treatment type and sex. We did multivariable analyses in the independent cohorts, and combined adjusted hazard ratios in a mixed-effects meta-analysis to provide a precise estimate of the association between BMI and survival outcomes; heterogeneity was assessed with meta-regression analyses. Analyses were done on the predefined intention-to-treat population in the randomised controlled trials and on all patients included in the retrospective study.Findings The six cohorts consisted of a total of 2046 patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy between Aug 8, 2006, and Jan 15, 2016. 1918 patients were included in the analysis. Two cohorts containing patients from randomised controlled trials treated with targeted therapy (dabrafenib plus trametinib [n=599] and vemurafenib plus cobimetinib [n=240]), two cohorts containing patients treated with immunotherapy (one randomised controlled trial of ipilimumab plus dacarbazine [n=207] and a retrospective cohort treated with pembrolizumab, nivolumab, or atezolizumab [n=331]), and two cohorts containing patients treated with chemotherapy (two randomised controlled trials of dacarbazine [n=320 and n=221]) were classified according to BMI as normal (694 [36%] patients), overweight (711 [37%]), or obese (513 [27%]). In the pooled analysis, obesity, compared with normal BMI, was associated with improved survival in patients with metastatic melanoma (average adjusted hazard ratio [HR] 0·77 [95% CI 0·66-0·90] for progression-free survival and 0·74 [0·58-0·95] for overall survival). The survival benefit associated with obesity was restricted to patients treated with targeted therapy (HR 0·72 [0·57-0·91] for progression-free survival and 0·60 [0·45-0·79] for overall survival) and immunotherapy (HR 0·75 [0·56-1·00] and 0·64 [0·47-0·86]). No associations were observed with chemotherapy (HR 0·87 [0·65-1·17, p interaction=0·61] for progression-free survival and 1·03 [0·80-1·34, p interaction=0·01] for overall survival). The association of BMI with overall survival for patients treated with targeted and immune therapies differed by sex, with inverse associations in men (HR 0·53 [0·40-0·70]), but no associations observed in women (HR 0·85 [0·61-1·18, p interaction=0·03]).Interpretation Our results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations.Funding ASCO/CCF Young Investigator Award, ASCO/CCF Career Development Award, MD Anderson Cancer Center (MDACC) Melanoma Moonshot Program, MDACC Melanoma SPORE, and the Dr Miriam and Sheldon G Adelson Medical Research Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30078-0

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Fang S Wang Y Dang Y Association between body mass index, C-reactive protein levels, and melanoma patient outcomes J Invest Dermatol 2017 28442307

Cited by

See all 670

Metadata

Authors
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., Lane, S., Lee, D.-Y., Kaper, M., McKean, M., Beckermann, K. E., Rubinstein, S. M., Rooney, I., Musib, L., Budha, N., Hsu, J., Nowicki, T. S., Avila, A., Haas, T., Puligandla, M., Lee, S., Fang, S., Wargo, J. A., Gershenwald, J. E., Lee, J. E., Hwu, P., Chapman, P. B., Sosman, J. A., Schadendorf, D., Grob, J.-J., Flaherty, K. T., Walker, D., Yan, Y., McKenna, E., Legos, J. J., Carlino, M. S., Ribas, A., Kirkwood, J. M., Long, G. V., Johnson, D. B., Menzies, A. M., & Davies, M. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Vanderbilt University Medical Center (US)
  • The University of Sydney (AU)
  • Westmead Hospital (AU)
  • Genentech (US)
  • University of California, Los Angeles (US)
  • Bristol-Myers Squibb (United States) (US)
  • Dana-Farber Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Northwestern University (US)
  • Essen University Hospital (DE)
  • Aix-Marseille Université (FR)
  • Massachusetts General Hospital (US)
  • UPMC Hillman Cancer Center (US)
Corresponding author
McQuade, Jennifer L
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-03
Volume
19
Issue
3
Pages
310-322
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2786396800
Cited by
664
References
33
Citations by year
2026: 49 · 2025: 67 · 2024: 79 · 2023: 89 · 2022: 90 · 2021: 100 · 2020: 95 · 2019: 61 · 2018: 33
FWCI
27.16
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Cancer Institute (P50CA221703)
  • California Community Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • American Society of Clinical Oncology
  • National Institutes of Health (CA009666)
  • National Health and Medical Research Council (K23 CA204726)
  • Cancer Institute NSW (1 R01 CA187076-01)
  • University of Sydney
  • University of Texas MD Anderson Cancer Center
  • Prometheus
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
metastatic melanoma, body mass index, obesity, overweight, progression-free survival, overall survival, targeted therapy, immunotherapy, chemotherapy, dabrafenib plus trametinib, pembrolizumab, nivolumab, atezolizumab, dacarbazine
MeSH terms
Antineoplastic Agents, Immunological, Progression-Free Survival, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Obesity, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Body Mass Index, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Young Adult, Molecular Targeted Therapy, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30078-0
The paper
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., Lane, S., Lee, D.-Y., Kaper, M., McKean, M., Beckermann, K. E., Rubinstein, S. M., Rooney, I., Musib, L., Budha, N., . . . Davies, M. A. (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30078-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.